Dr. Flavia Mafra de Lima received her degree in Physiotherapy from Claretiano University in 2005, Brazil. During the four years of the degree in all the vacations period she used to work as a voluntary physiotherapist in a General Hospital in Passos-MG, Brazil, in a ambulatory and intensive care, and in a cancer hospital in Sao Paulo, Brazil, with the ambulatory patients. When she finished her degree, she did a Specialization in a Sao Francisco Hospital in Brazil working in ambulatory, UCI, and Coronary Unit Intensive Care, and at the same time she did a Pos Graduation at Claretiano University in Intensive Care. In 2010, Mafra de Lima finished her Master’s in Biomedical Engineering with emphasis in Respiratory Medicine - Working with Acute Respiratory Distress Syndome (ARDS) and Low Level Laser Therapy (LLLT). Mafra de Lima started her PhD in 2011 in Rehabilitation Science, she continued working with ARDS and LLLT but at that time, she did a dose response investigation, which is still relevant today for all communities that works with LLLT and Lungs. In her first Post Doctoral studies, she worked with lung fibrosis and LLLT during one year at the Department of Immunology at University of Sao Paulo -USP, Brazil. In her second Post Doctoral studies, she has been working with kidney fibrosis and LLLT at Federal University of Sao Paulo- UNIFESP, Brazil, at the Department of Immunology and Nephrology, her studies was to compare if the treatment with LLLT is effective in another type of fibrosis as detected in the lungs. Nowadays, she is PostDoctoral Fellow, at Queen Mary University of London, at the Department of Biopharmacology, working with endogenous mediators of inflammation, with Prof. Dr. Mauro Perretti and Dr. Lucy Norling, finishing her second PostDoctoral.

Dr. Flavia Mafra de Lima has an interest in Lung Diseases because this diseases present high mortality according to the WHO Global Status Report on NCDs 2010, smoking is estimated to cause about 71% of all lung cancer deaths and 42% of chronic respiratory diseases worldwide, and in Europe, the high prevalence is at nearly 29%. Children and adults expose to poor air quality indoors are at great risk of being affected by outdoors pollutants, increasing the development of asthma. Long term exposure to particulate matters determines the risk of chronic diseases, as the pollution that we are exposed to every day in the huge city centres. ARDS, lung fibrosis, asthma, COPD, mechanical ventilation, bioengineering, Low Level Laser Therapy, Resolution of inflammation and GPCR’s mediators, Stem Cells, Regeneration, Lung Disease by pollution, Diseases pathways for resolution and regeneration.